Your browser doesn't support javascript.
loading
Long-term safety, efficacy, pharmacokinetics and pharmacodynamics of omalizumab in children with severe uncontrolled asthma.
Odajima, Hiroshi; Ebisawa, Motohiro; Nagakura, Toshikazu; Fujisawa, Takao; Akasawa, Akira; Ito, Komei; Doi, Satoru; Yamaguchi, Koichi; Katsunuma, Toshio; Kurihara, Kazuyuki; Teramoto, Takahide; Sugai, Kazuko; Nambu, Mitsuhiko; Hoshioka, Akira; Yoshihara, Shigemi; Sato, Norio; Seko, Noriko; Nishima, Sankei.
Afiliación
  • Odajima H; Department of Pediatrics, Fukuoka National Hospital, Fukuoka, Japan. Electronic address: odaji@mfukuoka2.hosp.go.jp.
  • Ebisawa M; Department of Allergy, Clinical Research Center for Allergology and Rheumatology, Sagamihara National Hospital, Sagamihara, Japan.
  • Nagakura T; Yoga Allergy Clinic, Tokyo, Japan.
  • Fujisawa T; Institute for Clinical Research, Mie National Hospital, Tsu, Japan.
  • Akasawa A; Division of Allergy, Tokyo Metropolitan Children's Medical Center, Tokyo, Japan.
  • Ito K; Department of Allergy, Aichi Children's Health and Medical Center, Obu, Japan.
  • Doi S; Department of Pediatrics, Osaka Prefectural Medical Center for Respiratory and Allergic Diseases, Habikino, Japan.
  • Yamaguchi K; Department of Pediatrics, The Fraternity Memorial Hospital, Tokyo, Japan.
  • Katsunuma T; Department of Pediatrics, Jikei Daisan Hospital, Tokyo, Japan.
  • Kurihara K; Department of Allergy, Kanagawa Children's Medical Center, Yokohama, Japan.
  • Teramoto T; Department of Pediatrics, Graduate School of Medicine, Gifu University, Gifu, Japan.
  • Sugai K; Department of Pediatrics, Fukuyama Medical Center, Fukuyama, Japan.
  • Nambu M; Department of Pediatrics, Tenri Hospital, Tenri, Japan.
  • Hoshioka A; Department of Allergy and Rheumatology, Chiba Children's Hospital, Chiba, Japan.
  • Yoshihara S; Department of Pediatrics, Dokkyo Medical University, Tochigi, Japan.
  • Sato N; Clinical Development, Novartis Pharma K.K., Tokyo, Japan.
  • Seko N; Clinical Development, Novartis Pharma K.K., Tokyo, Japan.
  • Nishima S; Department of Pediatrics, Fukuoka National Hospital, Fukuoka, Japan.
Allergol Int ; 66(1): 106-115, 2017 Jan.
Article en En | MEDLINE | ID: mdl-27507228
Asunto(s)
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Asma / Omalizumab Tipo de estudio: Clinical_trials / Observational_studies / Prognostic_studies / Risk_factors_studies Límite: Adolescent / Child / Female / Humans / Male Idioma: En Revista: Allergol Int Asunto de la revista: ALERGIA E IMUNOLOGIA Año: 2017 Tipo del documento: Article
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Asma / Omalizumab Tipo de estudio: Clinical_trials / Observational_studies / Prognostic_studies / Risk_factors_studies Límite: Adolescent / Child / Female / Humans / Male Idioma: En Revista: Allergol Int Asunto de la revista: ALERGIA E IMUNOLOGIA Año: 2017 Tipo del documento: Article